Friday 9 June 2006
The Institute of Cancer Research is delighted to have been designated an Experimental Cancer Medicine Centre in partnership with The Royal Marsden NHS Foundation Trust. The new funding will ensure that research at The Institute retains its position at the forefront of cancer drug development and should ultimately improve treatment options for patients.
The work will form part of a network of centres which will receive, in total, £35 million of funding over the next five years from The Department of Health and Cancer Research UK. The funding will commence in April 2007.
This initiative will build on the achievements of the Drug Development Unit which has taken 25 potential treatments into Phase I clinical trial in the past five years.
The new funding will consolidate activities at the Royal Marsden and The Institute, establishing a comprehensive environment for the discovery and assessment of new cancer treatments for the next decade.
Professor Stan Kaye, Cancer Research UK Professor of Medical Oncology at The Institute of Cancer Research said, “We are delighted to have been awarded funding for the Experimental Cancer Medicine Centre. Here at The Institute and the Royal Marsden we are committed to drug development and over the past 20 years we have made a number of breakthroughs with global impact, such as the development of anti-cancer drug carboplatin. This funding will allow us to further enhance our drug development capabilities and ultimately should help bring new treatments to patients sooner.”
- ends -